{
    "clinical_study": {
        "@rank": "24864", 
        "arm_group": [
            {
                "arm_group_label": "Megavec", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Glivec", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this Study is to Assess Safety and Pharmacokinetics of megavec 400 mg\n      (Imatinib mesylate) under Fasted Conditions in Healthy Male Subjects."
        }, 
        "brief_title": "Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "-  Inclusion Criteria:\n\n               -  Healthy and male subjects aged 20 to 55 years\n\n               -  The subject has a Body weight \u226555 kg and ideal body weight (IBW) within \u00b120%\n\n               -  A Subject who was judged to be healthy by the investigator to participate in\n                  this study based on screening results (according to standard reference index\n                  updated recently)\n\n               -  A subject who provided written informed consent to participate in this study and\n                  cooperative with regard to compliance with study related constraints.\n\n          -  Exclusion Criteria:\n\n               -  A subject with sign or symptoms or previously diagnosed disease of respiratory,\n                  cardiovascular, endocrinology, liver, kidney, hematology, neurology and\n                  psychology function or other significant diseases and history\n\n               -  Known allergy or hypersensitivity to the study medication\n\n               -  AST or ALT greater than 1.25 times the upper limit of reference range or Total\n                  bilirubin greater than 1.25 times the upper limit of reference range base on\n                  screening results\n\n               -  A subject judged ineligible by the investigator to participate in this study for\n                  other reason containing clinical laboratory tests"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653314", 
            "org_study_id": "DW_MGV001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Megavec", 
                    "Glivec"
                ], 
                "intervention_name": "Megavec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Megavec", 
                    "Glivec"
                ], 
                "intervention_name": "Glivec", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imatinib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 26, 2012", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Megavec 400 mg (Imatinib Mesylate) Under Fasted Conditions in Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Adverse events, Physical exam, Vital sign, Laboratory, 12-lead-ECG", 
            "measure": "Safety", 
            "safety_issue": "Yes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653314"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "AUC and Cmax in plasma", 
            "measure": "Pharmacokinetics", 
            "safety_issue": "No"
        }, 
        "source": "Daewoong Pharmaceutical Co. LTD.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewoong Pharmaceutical Co. LTD.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}